The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1.
Eric Van Cutsem
Research Funding - Novartis
Kun-Huei Yeh
Consultant or Advisory Role - Novartis (U)
Honoraria - Novartis
Yung-Jue Bang
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Lin Shen
No relevant relationships to disclose
Jaffer A. Ajani
No relevant relationships to disclose
Yu-Xian Bai
No relevant relationships to disclose
Hyun Cheol Chung
No relevant relationships to disclose
Hong-Ming Pan
No relevant relationships to disclose
Keisho Chin
No relevant relationships to disclose
Kei Muro
No relevant relationships to disclose
Yeul Hong Kim
No relevant relationships to disclose
Heind Smith
Employment or Leadership Position - Novartis
Chiara Costantini
Employment or Leadership Position - Novartis
Sara Musalli
Employment or Leadership Position - Novartis
Syed Rizvi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Tarek Sahmoud
Employment or Leadership Position - Novartis
Atsushi Ohtsu
Honoraria - Chugai Pharma; Novartis; Roche; Taiho Pharmaceutical